Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 pseudogene 1 (ST6GALNAC4P1) is a human pseudogene that shares sequence similarity with the functional ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 (ST6GALNAC4) gene, which encodes an enzyme involved in sialylation of glycoproteins and glycolipids. As a pseudogene, ST6GALNAC4P1 is not known to encode a functional protein and is not considered a therapeutic target. While some pseudogenes can regulate gene expression or be implicated in genetic disorders through gene conversion, RNA interference, or serving as mutation “decoys,” there is no evidence for such activity with this specific pseudogene. However, like other pseudogenes, its high sequence similarity to its functional parent can pose challenges for genetic testing such as sequencing read misalignment, which may cause diagnostic errors. There are no known drugs, mechanisms, or biomarkers associated specifically with ST6GALNAC4P1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 pseudogene 1 (ST6GALNAC4P1).